Full Press Release Details
updated linvoseltamab pivotal data demonstrated strong rates and depth of response in patients with heavily pre treated multiple myeloma.
REGN
updated linvoseltamab pivotal data demonstrated strong rates and depth of response in patients with heavily pre treated multiple myeloma
Key Takeaway: updated linvoseltamab pivotal data demonstrated strong rates and depth of response in patients with heavily pre treated multiple myeloma